OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MKRS56

Makers Laboratories Ltd

PharmaceuticalsVerified

Makers Laboratories has a liquidity profile that is relatively strong, with a current ratio of 3.22, indicating the company can cover its short-term obligations more than three times over. However, the company reported negative operating cash flow of INR 40.79 million, which raises concerns about its ability to sustain operations without external financing. The company's debt-to-equity ratio is low at 0.07, suggesting minimal leverage and a conservative capital structure. In terms of profitability, Makers Laboratories has a return on equity (ROE) of 10.62% and a return on assets (ROA) of 5.06%, which are both positive but should be compared to industry medians to assess relative performance. The company's net income of INR 74.91 million is derived from a gross profit of INR 666.85 million, indicating a relatively healthy margin structure. The company's revenue is concentrated in the Indian market, with no disclosed international operations. Its segments include Pharmaceutical and Chemical Manufacturing, with no further breakdown of geographic or product line contributions provided in the data. This lack of diversification could pose a concentration risk if the Indian market experiences regulatory or economic shifts. Looking ahead, the company's revenue outlook is not explicitly provided, but the operating cash flow and free cash flow figures suggest a mixed financial trajectory. Free cash flow of INR 117.52 million indicates some capacity for reinvestment or shareholder returns, but the negative operating cash flow suggests ongoing operational challenges. The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no immediate pressure from share issuance or dilutive events. However, the negative operating cash flow could necessitate future financing, which may introduce dilution risk if not managed through internal cash generation. Recent filings and transcripts are not provided in the input data, so no specific events can be cited. However, the financial snapshot indicates a need for close monitoring of cash flow trends and capital structure decisions.

30-day price · MKRS+3.65 (+2.3%)
Low$130.65High$168.00Close$160.00As of15 May, 00:00 UTC
Profile
CompanyMakers Laboratories Ltd
TickerMKRS.BO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations, primarily in the Indian market, with product lines including Duramol, Artemak-AB, and Exylin.

Classification. Makers Laboratories is classified under the Pharmaceuticals industry within the Healthcare economic sector, with a confidence level of 0.92 based on verified market data.

Makers Laboratories has a liquidity profile that is relatively strong, with a current ratio of 3.22, indicating the company can cover its short-term obligations more than three times over. However, the company reported negative operating cash flow of INR 40.79 million, which raises concerns about its ability to sustain operations without external financing. The company's debt-to-equity ratio is low at 0.07, suggesting minimal leverage and a conservative capital structure. In terms of profitability, Makers Laboratories has a return on equity (ROE) of 10.62% and a return on assets (ROA) of 5.06%, which are both positive but should be compared to industry medians to assess relative performance. The company's net income of INR 74.91 million is derived from a gross profit of INR 666.85 million, indicating a relatively healthy margin structure. The company's revenue is concentrated in the Indian market, with no disclosed international operations. Its segments include Pharmaceutical and Chemical Manufacturing, with no further breakdown of geographic or product line contributions provided in the data. This lack of diversification could pose a concentration risk if the Indian market experiences regulatory or economic shifts. Looking ahead, the company's revenue outlook is not explicitly provided, but the operating cash flow and free cash flow figures suggest a mixed financial trajectory. Free cash flow of INR 117.52 million indicates some capacity for reinvestment or shareholder returns, but the negative operating cash flow suggests ongoing operational challenges. The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no immediate pressure from share issuance or dilutive events. However, the negative operating cash flow could necessitate future financing, which may introduce dilution risk if not managed through internal cash generation. Recent filings and transcripts are not provided in the input data, so no specific events can be cited. However, the financial snapshot indicates a need for close monitoring of cash flow trends and capital structure decisions.
Key takeaways
  • Makers Laboratories has a strong current ratio but reports negative operating cash flow, indicating potential liquidity challenges.
  • The company's ROE and ROA are positive but should be benchmarked against industry medians for a complete assessment.
  • Revenue is concentrated in the Indian market, with no international diversification disclosed.
  • Free cash flow is positive, suggesting some capacity for reinvestment or shareholder returns.
  • The company's debt-to-equity ratio is low, indicating a conservative capital structure.
  • The risk assessment highlights a medium liquidity risk and low dilution risk.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$1.21B
Gross profit$666.8M
Operating income$30.1M
Net income$74.9M
R&D
SG&A
D&A
SBC
Operating cash flow-$40.8M
CapEx-$39.4M
Free cash flow$117.5M
Total assets$1.48B
Total liabilities$774.4M
Total equity$705.1M
Cash & equivalents$6.5M
Long-term debt$50.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$705.1M
Net cash-$44.2M
Current ratio3.2
Debt/Equity0.1
ROA5.1%
ROE10.6%
Cash conversion-54.0%
CapEx/Revenue-3.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
MetricMKRSActivity
Op margin2.5%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin6.2%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin55.2%47.8% medp25 27.6% · p75 68.9%above median
CapEx / revenue-3.3%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity7.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 03:15 UTC#d474a7b0
Source: analysis-pipeline (hybrid)Generated: 2026-05-05 03:16 UTCJob: 00c45df9